Lionheart Health, Inc., a leader in bioelectric regeneration and longevity biotechnology, announced the filing of a non-provisional U.S. patent for its Bioelectric-Enhanced Klotho Nanoflowers, a platform designed to reverse aging and extend healthspan. The patent protects a system that combines nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.
The platform centers on engineered nanoflowers—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein that improves brain, kidney, cardiovascular, and metabolic health. They also restore mitochondrial function by enhancing ATP production and reducing oxidative stress, deliver targeted bioactive agents including peptides and CRISPRa activators, and act as nanozyme catalysts to reduce reactive oxygen species. Importantly, the nanoflowers are engineered to respond to Lionheart’s proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance.
“This invention represents the convergence of three of the most powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation,” said Howard J. Leonhardt, Founder and CEO of Lionheart Health. “Our goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably.”
The nanoflowers require bioelectric activation for optimal performance; the bioelectric signals open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release. Klotho expression increases due to both nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter pathways, creating a combined therapeutic benefit.
Klotho is widely recognized as a promising longevity molecule. Decreased Klotho levels are associated with accelerated aging, cognitive decline, inflammation, and kidney dysfunction. Lionheart’s platform enables targeted Klotho delivery inside mitochondrial and cellular compartments responsible for aging. “Bioelectric-enhanced Klotho nanoflowers give us a programmable, multi-modal tool to address the root causes of aging,” said Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation.
The patent filing adds to Lionheart Health’s growing intellectual property portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, and Klotho-based gene therapy. Lionheart is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program.
Learn more at LionheartHealthStim.com and LionheartLongevity.com.
